Cancer-associated genes
OwnerYoshie Yoshikawa, Sachiko Okamoto +5inventors
InventorsYoshie Yoshikawa, Sachiko Okamoto, Tomonori Oura, Junichi Mineno, Kiyozo Asada, Hiroshi Inoue, Masaki Mori
Life of this patent
Estimating the term…
Abstract
To provide a rapid, simple, easy and more accurate detection of a cancer or the like, and its application to a treatment having a high specificity. Cancer-associated genes of SEQ ID NOs: 1 to 264; a method for detecting a cancer on the basis of expression of the cancer-associated genes; an array based on the cancer-associated genes; a kit for detecting a cancer; and a method for suppressing proliferation of a cancer cell.
Claims17
A method for detecting a cancer, characterized by evaluating alteration of expression of at least one kind of gene selected from the group consisting of:
- (a) a gene comprising a nucleic acid having either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1 to 264 or a nucleotide sequence complementary thereto, wherein an expression level of the gene in a cancer cell is altered as compared to that in a normal cell;
- (b) a gene comprising a nucleic acid capable of hybridizing to a nucleic acid having either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1 to 264 or a nucleotide sequence complementary thereto under stringent conditions, wherein an expression level of the gene in a cancer cell is altered as compared to that in a normal cell;
- and
- (c) a gene of a nucleic acid having a nucleotide sequence having at least 80% sequence identity to either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1 to 264 or a nucleotide sequence complementary thereto, wherein an expression level of the gene in a cancer cell is altered as compared to that in a normal cell.
A nucleic acid comprising a sequence of a cancer-associated gene selected from the group consisting of:
- (a′) a nucleic acid having either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 66 to 264 or a nucleotide sequence complementary thereto, wherein the nucleic acid comprises the sequence of a gene of which expression level in a cancer cell is altered as compared to that in a normal cell;
- (b′) a nucleic acid capable of hybridizing to a nucleic acid having either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 66 to 264 or a nucleotide sequence complementary thereto under stringent conditions, wherein the nucleic acid comprises the sequence of a gene of which expression level in a cancer cell is altered as compared to that in a normal cell;
- and
- (c′) a nucleic acid having a nucleotide sequence having at least 80% sequence identity to either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 66 to 264 or a nucleotide sequence complementary thereto, wherein the nucleic acid comprises the sequence of a gene of which expression level in a cancer cell is altered as compared to that in a normal cell.
A method for suppressing proliferation of a cancer cell, characterized by suppressing proliferation of the cancer cell using a specific conjugate capable of specifically binding to:
- (1) at least one nucleic acid selected from the group consisting of:
- (A) a nucleic acid having either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1 to 264 or a nucleotide sequence complementary thereto, wherein the nucleic acid comprises the sequence of a gene of which expression level in a cancer cell is altered as compared to that in a normal cell;
- (B) a nucleic acid capable of hybridizing to a nucleic acid having either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1 to 264 or a nucleotide sequence complementary thereto under stringent conditions, wherein the nucleic acid comprises the sequence of a gene of which expression level in a cancer cell is altered as compared to that in a normal cell;
- and
- (C) a nucleic acid having a nucleotide sequence having at least 80% sequence identity to either a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 1 to 264 or a nucleotide sequence complementary thereto, wherein the nucleic acid comprises the sequence of a gene of which expression level in a cancer cell is altered as compared to that in a normal cell;
- or
- (2) a polypeptide encoded by the above (1).
Dependencies are inferred from the claim text.